Sanofi-Aventis cuts a further 400 US sales reps
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis is to cut yet more US sales positions as it reduces its focus on central nervous system disorders and prepares for generic competition to its portfolio, a leaked internal email has revealed.